Application of the IDSA guidelines for the use of antimicrobial agents in neutropenic patients: impact on reducing the use of glycopeptides

Infect Control Hosp Epidemiol. 2001 Oct;22(10):651-3. doi: 10.1086/501839.

Abstract

We evaluated the impact of applying the Infectious Diseases Society of America guidelines for febrile neutropenic patients in reducing the use of glycopeptides. Forty-five prior episodes of febrile neutropenia were compared to 97 episodes seen after application of the guidelines. Glycopeptide use was reduced from 73% to 43% of episodes (P=.0008), without changes in outcome.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Amikacin / therapeutic use
  • Anti-Bacterial Agents / therapeutic use*
  • Brazil
  • Cefepime
  • Ceftazidime / therapeutic use
  • Cephalosporins / administration & dosage
  • Child
  • Drug Therapy, Combination / therapeutic use*
  • Female
  • Fever / complications
  • Fever / drug therapy*
  • Hospitals, Teaching
  • Humans
  • Male
  • Middle Aged
  • Neutropenia / complications
  • Neutropenia / drug therapy*
  • Oxacillin / administration & dosage
  • Practice Guidelines as Topic*
  • Teicoplanin / therapeutic use
  • Treatment Outcome
  • Vancomycin / therapeutic use

Substances

  • Anti-Bacterial Agents
  • Cephalosporins
  • Teicoplanin
  • Vancomycin
  • Cefepime
  • Amikacin
  • Ceftazidime
  • Oxacillin